nach oben

Wiener Medizinische Wochenschrift

Erschienen in:

01.10.2012 | main topic

Nuclear medicine in NET

verfasst von: Manfred Sorschag, MD, Phillip Malle, Hans-Jürgen Gallowitsch

Erschienen in: Wiener Medizinische Wochenschrift | Ausgabe 19-20/2012

Einloggen, um Zugang zu erhalten

Summary

Neuroendocrine tumors (NET) are, despite increasing incidence, still rare, usually slow growing neoplasms with resemblance to nerve cells and the endocrine capability of hormone production. In contrast to commonly used conventional imaging procedures, nuclear imaging is feasible to visualize the presence of molecular biomarkers, particularly the overexpression of somatostatin receptors (sstr) with high diagnostic accuracy which has led to the establishment of somatostatin receptor scintigraphy (SRS) as essential component and gold standard of functional imaging in the workup of NET. Another major feature is the selection of patients with inoperable or metastasized tumors showing sufficient uptake for peptide receptor radionuclide therapy (PRRT). While somatostatin receptor PET and PET/CT using Ga-68-labeled SSR analogs represents the consistent further development of SRS, FDG-PET can only be used in tumors with high proliferative activity but not on a routine basis for imaging of neuroendocrine tumors. ¹⁸F-DOPA represents an alternative PET tracer worth mentioning currently under assessment for NET imaging.

Vorheriger Artikel The role of nuclear medicine in differentiated thyroid cancer

Nächster Artikel FDG PET and FDG PET/CT in patients with gastrointestinal stromal tumours

Kaserer K, Koperek O. Pathologie der neuroendokrinen Tumoren des Gastrointestinaltraktes und des Pankreas. Spectr Onkol. 2008;3(2008):8–12.

Rindi G, Arnold R, Bosman FT, et al. Nomenclature and classification of neuroendocrine neoplasms of the digestive system. In: Bosman TF, Carneiro F, Hruban RH, Theise ND. editors. Lyon: International Agency for Research on cancer (IARC); 2010. p. 13.

Yao JC, Hassan M, Phan A. et al. One hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol. 2008;26:3063–3072.PubMedCrossRef

Bornschein J, Kidd M, Malfertheiner P, Modlin IM. Gastrointestinal neuroendocrine tumors. Dtsch Med Wochenschr. 2008;133(28–29):1505–10.PubMedCrossRef

Niederle MB, Hackl M, Kaserer K, Niederle B. Gastroenteropancreatic neuroendocrine tumours: the current incidence and staging based on the WHO and European Neuroendocrine Tumour Society classification: an analysis based on prospectively collected parameters. Endocr Relat Cancer. 2010;17(4):909–18.PubMedCrossRef

Klöppel G, Couvelard A, Perren A, Komminoth P, McNicol AM, Nilsson O, Scarpa A, Scoazec JY, Wiedenmann B, Papotti M, Rindi G, Plöckinger U, participants, Mallorca Consensus Conference und Society., European Neuroendocrine Tumor. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: towards a standardized approach to the diagnosis of gastroenteropancreatic neuroendocrine tumors and their prognostic stratification. Neuroendocrinology. 2009;90(2):162–6. Epub 2009 Aug 28. No abstract available. Erratum in: Neuroendocrinology. 2009;90(4):432. Neuroendocrinology. 2010;92(4):251. Neuroendocrinology. 2010;92(3):197.

Ramage JK, Ahmed A, Ardill J, et al. (UK and Ireland Neuroendocrine Tumour Society). Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours (NETs). Gut. 61(1):6–32.

Reubi JC, Waser B, Schaer JC, Laissue JA. Somatostatin receptor sst1-sst5 expression in normal and neoplastic human tissues using receptor autoradiography with subtype-selective ligands. Eur J Nucl Med. 2001;28(7):836–46.PubMedCrossRef

Hoyer D, Bell GI, Berelowitz M, Epelbaum J, Feniuk W, Humphrey PP, O’Carroll AM, Patel YC, Schonbrunn A, Taylor JE, et al. Classification and nomenclature of somatostatin receptors. Trends Pharmacol Sci. 1995;16(3):86–8.PubMedCrossRef

10.

Reubi JC. Peptide receptor expression in GEP-NET. Virchows Arch. 2007;451(Suppl 1):47–50.CrossRef

11.

Krenning EP, Bakker WH, Kooij PP, Breeman WA, Oei HY, de Jong M, Reubi JC, Visser TJ, Bruns C, Kwekkeboom DJ, et al. Somatostatin receptor scintigraphy with indium-111-DTPA-D-Phe-1-octreotide in man: metabolism, dosimetry and comparison with iodine-123-Tyr-3-octreotide. J Nucl Med. 1992;33(5):652–8.PubMed

12.

Weiner RE, Thakur ML. Radiolabeled peptides in diagnosis and therapy. Semin Nucl Med. 2001;31(4):296–311.PubMedCrossRef

13.

Virgolini I, Leimer M, Handmaker H, Lastoria S, Bischof C, Muto P, Pangerl T, Gludovacz D, Peck-Radosavljevic M, Lister-James J, Hamilton G, Kaserer K, Valent P, Dean R. Somatostatin receptor subtype specificity and in vivo binding of a novel tumor tracer, 99mTc-P829. Cancer Res. 1998;58(9):1850–9.PubMed

14.

Gotthardt M, Dijkgraaf I, Boerman OC, Oyen WJ. Nuclear medicine imaging and therapy of neuroendocrine tumours. Cancer Imaging. 2006;6:178–84.CrossRef

15.

John M, Meyerhof W, Richter D, Waser B, Schaer JC, Scherübl H, Boese-Landgraf J, Neuhaus P, Ziske C, Mölling K, Riecken EO, Reubi JC, Wiedenmann B. Positive somatostatin receptor scintigraphy correlates with the presence of somatostatin receptor subtype 2. Gut. 1996;38(1):33–9.PubMedCrossRef

16.

Decristofero C, Mather SJ, Cholewinsky W et al. 99 m Tc-tricine-Hynic-TOC: a new 99 m Tc-labelled radiopharmaceutical for imaging somatostatin receptor positive tumors; first clinical results and intra patient comparison with 111 In-labelled octreotide derivates. Eur J Nucl Med. 2000;27(9):1318–25.CrossRef

17.

Bangard M, Béhé M, Guhlke S, Otte R, Bender H, Maecke HR, Biersack HJ. Detection of somatostatin receptor-positive tumours using the new 99 mTc-tricine-HYNIC-D-Phe1-Tyr3-octreotide: first results in patients and comparison with 111In-DTPA-D-Phe1-octreotide. Eur J Nucl Med. 2000;27(6):628–37.PubMedCrossRef

18.

Lebtahi R, Le Cloirec J, Houzard C, Daou D, Sobhani I, Sassolas G, Mignon M, Bourguet P, Le Guludec D. Detection of neuroendocrine tumors: 99 mTc-P829 scintigraphy compared with 111In-pentetreotide scintigraphy. J Nucl Med. 2002;43(7):889–95.PubMed

19.

Gabriel M, Decristoforo C, Donnemiller E, Ulmer H, Watfah Rychlinski C, Mather SJ, Moncayo R. An intrapatient comparison of 99 mTc-EDDA/HYNIC-TOC with 111In-DTPA-octreotide for diagnosis of somatostatin receptor-expressing tumors. J Nucl Med. 2003;44(5):708–16.PubMed

20.

Krenning EP, Kwekkeboom DJ, Bakker WH, Breeman WAP, Kooji PPM, Oei HY van Hagen M, Postema PTE, de Jong M, Reubi JC, Visser TJ Reijs AEM, Hofland LJ, Koper JW, Lamberts SWJ. Somatostatin receptor scintigraphy with [111 In-DTPA-D-Phe1] und [123 I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients. Eur J Nucl Med. 1993;20(8):716–31.PubMedCrossRef

21.

de Herder WW, Kwekkeboom DJ, Valkema R, Feelders RA, van Aken MO, Lamberts SW, Van Der Lely AJ, Krenning EP. Neuroendocrine tumors and somatostatin: imaging techniques. J Endocrinol Invest. 2005;28(11 Suppl International):132–6.PubMed

22.

Kwekkeboom DJ, Krenning EP, Scheidhauer K, Lewington V, Lebtahi R, Grossman A, Vitek P, Sundin A, Plöckinger U, participants, Mallorca Consensus Conference und Society., European Neuroendocrine Tumor. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: somatostatin receptor imaging with (111)In-pentetreotide. Neuroendocrinology. 2009;90(2):184–9. Epub 2009 Aug 28.

23.

Raderer M, Kurtaran A, Leimer M, Angelberger P, Niederle B, Vierhapper H, Vorbeck F, Hejna MH, Scheithauer W, Pidlich J, Virgolini I. Value of peptide receptor scintigraphy using (123)I-vasoactive intestinal peptide and (111)In-DTPA-D-Phe1-octreotide in 194 carcinoid patients: Vienna University Experience, 1993–1998. J Clin Oncol. 2000;18(6):1331–6.PubMed

24.

Koopmans KP, Neels ON, Kema IP, Elsinga PH, Links TP, de Vries EG, Jager PL. Molecular imaging in neuroendocrine tumors: molecular uptake mechanisms and clinical results. Crit Rev Oncol Hematol. 2009;71(3):199–213.PubMedCrossRef

25.

Adams S, Baum R, Rink T, Schumm-Dräger PM, Usadel KH, Hör G. Limited value of fluorine-18 fluorodeoxyglucose positron emission tomography for the imaging of neuroendocrine tumours. Eur J Nucl Med. 1998;25(1):79–83.PubMedCrossRef

26.

Binderup T, Knigge U, Loft A, Federspiel B, Kjaer A. 18F-fluorodeoxyglucose positron emission tomography predicts survival of patients with neuroendocrine tumors. Clin Cancer Res. 2010;16(3):978–85.PubMedCrossRef

27.

Binderup T, Knigge U, Loft A, Mortensen J, Pfeifer A, Federspiel B, Hansen CP, Højgaard L, Kjaer A. Functional imaging of neuroendocrine tumors: a head-to-head comparison of somatostatin receptor scintigraphy, 123I-MIBG scintigraphy, and 18F-FDG PET. J Nucl Med. 2010;51(5):704–12.PubMedCrossRef

28.

Belhocine T, Foidart J, Rigo P, Najjar F, Thiry A, Quatresooz P, Hustinx R. Fluorodeoxyglucose positron emission tomography and somatostatin receptor scintigraphy for diagnosing and staging carcinoid tumours: correlations with the pathological indexes p53 and Ki-67. Nucl Med Commun. 2002;23(8):727–34.PubMedCrossRef

29.

Eriksson B, Bergström M, Orlefors H, Sundin A, Oberg K, Långström B. Use of PET in neuroendocrine tumors. In vivo applications and in vitro studies. Q J Nucl Med. 2000;44(1):68–76.PubMed

30.

Hofmann M, Maecke H, Börner R, Weckesser E, Schöffski P, Oei L, Schumacher J, Henze M, Heppeler A, Meyer J, Knapp H. Biokinetics and imaging with the somatostatin receptor PET radioligand (68)Ga-DOTATOC: preliminary data. Eur J Nucl Med. 2001;28(12):1751–7.PubMedCrossRef

31.

Ambrosini V, Tomassetti P, Franchi R, Fanti S. Imaging of NETs with PET radiopharmaceuticals. Q J Nucl Med Mol Imaging. 2010;54(1):16–23.PubMed

32.

Buchmann I, Henze M, Engelbrecht S, Eisenhut M, Runz A, Schäfer M, Schilling T, Haufe S, Herrmann T, Haberkorn U. Comparison of 68Ga-DOTATOC PET and 111In-DTPAOC (Octreoscan) SPECT in patients with neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2007;34(10):1617–26.PubMedCrossRef

33.

Ambrosini V, Nanni C, Zompatori M, Campana D, Tomassetti P, Castellucci P, Allegri V, Rubello D, Montini G, Franchi R, Fanti S. (68)Ga-DOTA-NOC PET/CT in comparison with CT for the detection of bone metastasis in patients with neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2010;37(4):722–7.PubMedCrossRef

34.

Krausz Y, Freedman N, Rubinstein R, Lavie E, Orevi M, Tshori S, Salmon A, Glaser B, Chisin R, Mishani E, J Gross D. 68Ga-DOTA-NOC PET/CT imaging of neuroendocrine tumors: comparison with In-DTPA-octreotide (OctreoScanâ). Mol Imaging Biol. 2011;13(3):583–93.PubMedCrossRef

35.

Teunissen JJ, Kwekkeboom DJ, Valkema R, Krenning EP. Nuclear medicine techniques for the imaging and treatment of neuroendocrine tumours. Endocr Relat Cancer. 2011;18(Suppl 1):27–51.CrossRef

36.

Minn H, Kauhanen S, Seppänen M, Nuutila P. 18F-FDOPA: a multiple-target molecule. J Nucl Med. 2009;50(12):1915–8.PubMedCrossRef

37.

Gazdar AF, Helman LJ, Israel MA, Russell EK, Linnoila RI, Mulshine JL, Schuller HM, Park JG. Expression of neuroendocrine cell markers L-dopa decarboxylase, chromogranin A, and dense core granules in human tumors of endocrine and nonendocrine origin. Cancer Res. 1988;48(14):4078–82.PubMed

38.

Gazdar AF, Helman LJ, Israel MA, et al. Expression of neuroendocrine cell markers L-dopa decarboxylase, chromogranin A, and dense core granules in human tumors of endocrine and nonendocrine origin. Cancer Res. 1988;48:4078–4082.PubMed

39.

Montravers F, Grahek D, Kerrou K, Ruszniewski P, de Beco V, Aide N, Gutman F, Grangé JD, Lotz JP, Talbot JN. Can fluorodihydroxyphenylalanine PET replace somatostatin receptor scintigraphy in patients with digestive endocrine tumors? J Nucl Med. 2006;47(9):1455–62.PubMed

40.

Koopmans KP, Neels OC, Kema IP, Elsinga PH, Sluiter WJ, Vanghillewe K, Brouwers AH, Jager PL, de Vries EG. Improved staging of patients with carcinoid and islet cell tumors with 18F-dihydroxy-phenyl-alanine and 11C-5-hydroxy-tryptophan positron emission tomography. J Clin Oncol. 2008;26(9):1489–95.PubMedCrossRef

41.

Hoegerle S, Altehoefer C, Ghanem N, Koehler G, Waller CF, Scheruebl H, Moser E, Nitzsche E. Whole-body 18F dopa PET for detection of gastrointestinal carcinoid tumors. Radiology. 2001;220(2):373–80.PubMed

42.

Becherer A, Szabó M, Karanikas G, Wunderbaldinger P, Angelberger P, Raderer M, Kurtaran A, Dudczak R, Kletter K. Imaging of advanced neuroendocrine tumors with (18)F-FDOPA PET. J Nucl Med. 2004;45(7):1161–7.PubMed

43.

Ambrosini V, Tomassetti P, Castellucci P, Campana D, Montini G, Rubello D, Nanni C, Rizzello A, Franchi R, Fanti S. Comparison between 68Ga-DOTA-NOC and 18F-DOPA PET for the detection of gastro-entero-pancreatic and lung neuro-endocrine tumours. Eur J Nucl Med Mol Imaging. 2008;35(8):1431–8.PubMedCrossRef

44.

Orlefors H, Sundin A, Garske U, Juhlin C, Oberg K, Skogseid B, Langstrom B, Bergstrom M, Eriksson B. Whole-body (11)C-5-hydroxytryptophan positron emission tomography as a universal imaging technique for neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and computed tomography. J Clin Endocrinol Metab. 2005;90(6):3392–400.PubMedCrossRef

Titel: Nuclear medicine in NET
verfasst von: Manfred Sorschag, MD
Phillip Malle
Hans-Jürgen Gallowitsch
Publikationsdatum: 01.10.2012
Verlag: Springer Vienna
Erschienen in: Wiener Medizinische Wochenschrift / Ausgabe 19-20/2012
Print ISSN: 0043-5341
Elektronische ISSN: 1563-258X
DOI: https://doi.org/10.1007/s10354-012-0130-z

Springer Medizin Österreich

Summary

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 19-20/2012

Nuclear medicine and oncology

Coping with job stress by hospital doctors: a comparative study

Angiolymphoid hyperplasia with eosinophilia—an incidental finding after surgical excision

The role of nuclear medicine in differentiated thyroid cancer

Radionuclide therapy beyond radioiodine

FDG PET and FDG PET/CT in patients with gastrointestinal stromal tumours